Zentalis Pharmaceuticals, Inc.
ZNTL
$1.51
$0.021.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.87M | -48.28M | -94.97M | -40.16M | -88.28M |
| Total Depreciation and Amortization | 160.00K | 262.00K | 317.00K | 321.00K | 327.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 334.00K | 13.63M | 29.09M | 3.05M | 39.48M |
| Change in Net Operating Assets | -8.33M | 1.75M | -7.08M | -7.26M | 13.33M |
| Cash from Operations | -34.71M | -32.64M | -39.70M | -44.05M | -35.14M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | -181.00K |
| Sale of Property, Plant, and Equipment | 564.00K | 5.00K | 0.00 | 0.00 | 65.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.81M | 40.47M | 32.28M | 48.24M | 34.61M |
| Cash from Investing | 30.38M | 40.48M | 32.28M | 48.24M | 34.49M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 189.00K | 0.00 | 92.00K | 9.00K |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 189.00K | 0.00 | 92.00K | 9.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.33M | 8.03M | -7.42M | 4.29M | -640.00K |